(Q40772706)

23 September 2017

1 reference

title

Antiplatelet therapy in the treatment of cerebrovascular disease (English)

1 reference

23 September 2017

Couch JR

1

1 reference

23 September 2017

language of work or name

1 reference

1 October 1993

1 reference

23 September 2017

1 reference

23 September 2017

volume

16

1 reference

23 September 2017

issue

10

1 reference

23 September 2017

page(s)

703-710

1 reference

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Survival and recurrence following stroke. The Framingham study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Natural history of stroke in Rochester, Minnesota, 1955 through 1969: an extension of a previous study, 1945 through 1954.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Single studies and overview analyses: is aspirin of value in cerebral ischemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Incidence rates of stroke in the eighties: the end of the decline in stroke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Controlled trial of aspirin in cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Stroke recurrence within 2 years after ischemic infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Probability of stroke: a risk profile from the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

Factors influencing the prognosis of cerebral thrombosis and infarction due to atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

Meta-analysis of relation between cigarette smoking and stroke

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

Differential Inhibition by Aspirin of Vascular and Platelet Prostaglandin Synthesis in Atherosclerotic Patients

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

The pathogenesis of atherosclerosis--an update

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960161004

7 January 2021

Identifiers

DOI

10.1002/CLC.4960161004

1 reference

23 September 2017

1 reference